Evaluation of Omeprazole Effect on Glaucoma

Glaucoma Clinical Trial

Official title:

Evaluation of Omeprazole Effect on Glaucoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01000220
• Other study ID #: 8735
• Status: Recruiting
• Phase: Phase 1
• First received: July 7, 2009
• Last updated: May 3, 2010

Study information

• Verified date: October 2009
• Source: hahid Beheshti University of Medical Sciences
• Contact: Yazdani Shahin, MD
• Phone: +982122585952
• Email: labbafi[@]hotmail.com
• Is FDA regulated: No
• Health authority: Iran: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Description:

Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• patients with glaucoma

• 18 to 70 years

• POAG patients, Pseudoexfoliation

• no history of other systemic disease

• no history of intraocular intervention

• no history of H2 blocker or PPI consumption during the past month consuming 2 or less topical anti-glaucoma medication

• no present immune deficiency

• no addiction habit

Exclusion Criteria:

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glaucoma

Intervention

Drug:
• Omeprazole

• Placebo

Locations

Country	Name	City	State
Iran, Islamic Republic of	Ophthalmic Research Center	Tehran

Sponsors (2)

Lead Sponsor	Collaborator
hahid Beheshti University of Medical Sciences	Ophthalmic Research Center

Country where clinical trial is conducted

Iran, Islamic Republic of,